Acne crème to Reduce Propionibacterium Acnes Load in Primary Shoulder Surgery
NCT ID: NCT03949751
Last Updated: 2020-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2018-11-01
2020-05-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does the Addition of Hydrogen Peroxide to Chlorhexidine Skin Prep to Treat P. Acnes in the Shoulder
NCT03656588
Cutibacterium Acnes in Deep Tissues in Primary Spine and Shoulder Surgery
NCT05355844
Photodynamic Therapy for Cutibacterium Acnes (C. Acnes) Decolonization of the Shoulder Dermis
NCT04636242
Blue Light Therapy of C. Acnes
NCT04300010
Topical Treatment and Prevalence of P. Acnes
NCT03257202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators suppose that the patients with the local therapy (therapy group) show fewer positive samples than the patients of the control group as the combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, approval number 47033, Swissmedic) is used in the therapy of acne where Propionibacterium acnes is the major pathogen. By decreasing the presence of Propionibacterium acnes, infections and revision surgeries could be reduced as well. The investigators expect a higher rate of positive cultures from the subcutaneous layer compared to the superficial and to the deep layer. The investigators await more positive cultures in men than in women as men show a higher density of the glands in the subcutaneous layer where Propionibacterium acnes is linked to. For the same reason, the investigators suppose also a higher number of positive culture samples in younger patients (≤40 years) than in older patients (\>40 years).
60 patients undergoing first time open shoulder surgery (Latarjet, prosthesis) will be prospectively included in this study. The investigators will do a randomized controlled trial, choosing with a single-blinded protocol 30 patients for local therapy and other 30 patients as the control group without any treatment preoperative. In the preoperative consultation 30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. 30 patients will be included in the control group. Those patients will not get the local therapy in the preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative. In the operation room there will be done from each of the 60 patients a superficial skin swab before doing disinfection, a swab of the subcutaneous layer and a swab of the deep layer (joint capsule). All the three swabs from each of the 60 patients will be sent to Unilabs, Labor für Medizinische Analytik AG, Dübendorf, Switzerland to streak on agar plates to cultivate under anaerobic conditions for 14 days. Propionibacterium acnes will be identified by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The number of positive culture samples from the therapy group will be compared with the number of positive culture samples from the control group.
Determination of Sample Size was done by performing a power analysis using www.clincalc.com, a sample size calculator placed at disposal by Sean P. Kane (clinical pharmacist, assistant professor at Rosalind Franklin University of Medicine and Science, North Chicago and advocate of evidence-based medicine). The study groups are two independent groups as they receive different treatments. The primary endpoint is dichotomous. The anticipated incidence of the therapy group is defined as 30%, the incidence of the control group is supposed to be 3-5% and the enrolment ratio is 1. The probability of a type-I-error is 0.05. With obtaining a power of 80%, between 56 and 70 participants are needed for the study according to the sample size calculator.
Recent studies could show that 30% of the patients without any obvious signs for infection and no preliminary operation have positive culture samples for Propionibacterium acnes, the investigators expect this result as well. The investigators suppose that the patients with the local therapy (therapy group) show fewer positive samples than the patients of the control group as the combination of Benzoylperoxid and Miconazolnitrat is used in the therapy of acne where Propionibacterium acnes is the major pathogen. As it is known that Propionibacterium acnes resides in the subcutaneous layer, the investigators expect a higher rate of positive cultures from the subcutaneous layer compared to the superficial and to the deep layer. The investigators expect more positive cultures in men than in women as men show a higher density of the glands in the subcutaneous layer where Propionibacterium acnes is linked to. The investigators suppose also a higher number of positive culture samples in younger patients (≤40 years) than in older patients (\>40 years).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
The participants of the control group will not get the local therapy in the investigator's preoperative consultation but they will need to give written consent for taking swabs for culture samples pre- and intraoperative.
No interventions assigned to this group
Therapy group
30 patients will get Acne Crème Plus (Benzoylperoxid and Miconazolnitrat) to apply until operation (on average 7 days) after receiving written consent. The application should be done daily in the evening on the planned operative side covering the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae.
Acne Crème Plus
The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acne Crème Plus
The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female patients
* Age \> 18 years
* Competent German language skills
* Written informed consent as documented by signature (Appendix Informed Consent Form)
Exclusion Criteria
* known or suspected non-compliance, drug or alcohol abuse,
* participation in another study with investigational drug within the 30 days preceding and during the present study,
* pregnancy or breast feeding (see chapter 3.7),
* preliminary shoulder surgeries,
* patients planned for an arthroscopic shoulder surgery,
* hypersensitivity to Benzoylperoxid or Miconazol,
* use of other acne preparations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Balgrist University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samy Bouaicha, PD Dr.med.
Role: PRINCIPAL_INVESTIGATOR
Balgrist University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Balgrist
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Padegimas EM, Lawrence C, Narzikul AC, Zmistowski BM, Abboud JA, Williams GR, Namdari S. Future surgery after revision shoulder arthroplasty: the impact of unexpected positive cultures. J Shoulder Elbow Surg. 2017 Jun;26(6):975-981. doi: 10.1016/j.jse.2016.10.023. Epub 2017 Jan 10.
Achermann Y, Sahin F, Schwyzer HK, Kolling C, Wust J, Vogt M. Characteristics and outcome of 16 periprosthetic shoulder joint infections. Infection. 2013 Jun;41(3):613-20. doi: 10.1007/s15010-012-0360-4. Epub 2012 Nov 3.
Levy O, Iyer S, Atoun E, Peter N, Hous N, Cash D, Musa F, Narvani AA. Propionibacterium acnes: an underestimated etiology in the pathogenesis of osteoarthritis? J Shoulder Elbow Surg. 2013 Apr;22(4):505-11. doi: 10.1016/j.jse.2012.07.007. Epub 2012 Sep 13.
Dodson CC, Craig EV, Cordasco FA, Dines DM, Dines JS, Dicarlo E, Brause BD, Warren RF. Propionibacterium acnes infection after shoulder arthroplasty: a diagnostic challenge. J Shoulder Elbow Surg. 2010 Mar;19(2):303-7. doi: 10.1016/j.jse.2009.07.065. Epub 2009 Nov 1.
Phadnis J, Gordon D, Krishnan J, Bain GI. Frequent isolation of Propionibacterium acnes from the shoulder dermis despite skin preparation and prophylactic antibiotics. J Shoulder Elbow Surg. 2016 Feb;25(2):304-10. doi: 10.1016/j.jse.2015.08.002. Epub 2015 Oct 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
W728
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.